State funding awarded in efforts to validate TruDiagnostic’s new imprintome array for use by researchers

March 03, 2022

Lexington, KY – TruDiagnostic recently created a new imprintome array, developed with the help of Illumina and our partners at North Carolina State University

Imprintome Control Regions (ICRs) are chromosomal regions that act, in a methylation-sensitive way, to determine whether imprinted genes are expressed or not according to the parent from which the gene derived. We hope that this array will help researchers investigate the mechanistic underpinnings of imprintome-related diseases such as Alzheimer’s disease, autism, and obesity – among many others.

We are working to create a validation of the array’s technical function on an imprintome-associated disease. To that end, Dr. Jessica Lasky-Su will be advising us on a grant proposal to the U.S. National Institutes of Health (NIH) on the impact of ICRs on disease phenotypes. Dr. Lasky-Su will also help us design a research study using cohorts from the Harvard Partners’ Biobank that include longitudinal phenotype measurements.

To assist in our pursuit of funding from the NIH for this exciting project, TruDiagnostic is delighted to announce that we’ve received an award from the Kentucky Science and Technology Corporation and the Kentucky Science and Engineering Foundation. Funding is provided through the Kentucky Cabinet for Economic Development. These dollars will support the consulting work with Dr. Lasky-Su.

We would like to earnestly thank the folks over at the KSTC and KSEF for granting this award, and we look forward to the validation process of this array.